Business Description
Profound Medical Corp
NAICS : 621511
SIC : 8689
ISIN : CA74319B1067
Description
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.12 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.23 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 2.99 | |||||
| Beneish M-Score | -2.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.5 | |||||
| 3-Year EBITDA Growth Rate | -5.5 | |||||
| 3-Year EPS without NRI Growth Rate | -6.8 | |||||
| 3-Year FCF Growth Rate | 3.1 | |||||
| 3-Year Book Growth Rate | -31.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 26.88 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 102.63 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.32 | |||||
| 9-Day RSI | 49.01 | |||||
| 14-Day RSI | 45.57 | |||||
| 6-1 Month Momentum % | -1.37 | |||||
| 12-1 Month Momentum % | -3.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.61 | |||||
| Quick Ratio | 7.42 | |||||
| Cash Ratio | 6.05 | |||||
| Days Inventory | 861.64 | |||||
| Days Sales Outstanding | 310.34 | |||||
| Days Payable | 316.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | -13.15 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 61.29 | |||||
| Operating Margin % | -388.85 | |||||
| Net Margin % | -349.82 | |||||
| FCF Margin % | -289.38 | |||||
| ROE % | -69.48 | |||||
| ROA % | -53.53 | |||||
| ROIC % | -217.86 | |||||
| 3-Year ROIIC % | 498.59 | |||||
| ROC (Joel Greenblatt) % | -235.31 | |||||
| ROCE % | -68.32 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 22.29 | |||||
| PB Ratio | 4.74 | |||||
| Price-to-Tangible-Book | 4.77 | |||||
| EV-to-EBIT | -5.04 | |||||
| EV-to-EBITDA | -5.25 | |||||
| EV-to-Revenue | 19.17 | |||||
| EV-to-Forward-Revenue | 4.8 | |||||
| EV-to-FCF | -6.77 | |||||
| Price-to-Net-Current-Asset-Value | 4.93 | |||||
| Price-to-Net-Cash | 8.02 | |||||
| Earnings Yield (Greenblatt) % | -19.84 | |||||
| FCF Yield % | -12.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PROF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Profound Medical Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.88 | ||
| EPS (TTM) ($) | -1.22 | ||
| Beta | 0.57 | ||
| Volatility % | 59.28 | ||
| 14-Day RSI | 45.57 | ||
| 14-Day ATR ($) | 0.275459 | ||
| 20-Day SMA ($) | 7.631555 | ||
| 12-1 Month Momentum % | -3.88 | ||
| 52-Week Range ($) | 7.11 - 11.69 | ||
| Shares Outstanding (Mil) | 24.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Profound Medical Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Profound Medical Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Profound Medical Corp Frequently Asked Questions
What is Profound Medical Corp(PROF)'s stock price today?
The current price of PROF is $7.54. The 52 week high of PROF is $11.69 and 52 week low is $7.11.
When is next earnings date of Profound Medical Corp(PROF)?
The next earnings date of Profound Medical Corp(PROF) is 2024-11-07.
Does Profound Medical Corp(PROF) pay dividends? If so, how much?
Profound Medical Corp(PROF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers